Stock

Gilead voluntarily withdraws urothelial cancer drug in US

(Reuters) – Gilead Sciences (NASDAQ:GILD) said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator.

This post appeared first on investing.com

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

More in:Stock